Anzeige
Erschienen in:
30.08.2016 | Original Article
Radioimmunotherapy with 131I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma
Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2016
Einloggen, um Zugang zu erhaltenAbstract
Purpose
The aim of this study was to assess the clinical activity and toxicity of 131I-rituximab as consolidation therapy for patients with diffuse large B-cell lymphoma (DLBCL) who were treated with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone).
Methods
Patients who had been diagnosed with advanced stage (Ann Arbor III or IV) or bulky stage II DLBCL and achieved complete or partial response after six to eight cycles of R-CHOP were enrolled.
Results
A total of 16 patients were enrolled and treated with a single dose of 131I-rituximab as consolidation therapy after the completion of six or eight cycles of R-CHOP between December 2005 and June 2011. This trial was terminated before the scheduled enrollment owing to low recruitment. Among the 16 patients who were treated with consolidative 131I-rituximab, 6 achieved complete response (CR) after three cycles of R-CHOP, and another 9 patients further achieved CR after the completion of six or eight cycles of R-CHOP. During the median follow-up period of 73 months, only four patients (25 %) experienced relapse. Two-year relapse-free survival was 88 %, and 5-year relapse-free survival was 81 %. Grade 3 or 4 treatment-related toxicity occurred in four patients and included neutropenia and thrombocytopenia.
Conclusions
131I-rituximab showed promising efficacy as consolidation treatment for patients with DLBCL. A future randomized phase III study to confirm our results is warranted.